Skip to main content

Evolus, Inc.

EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001570562

In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Evolus, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $950.0K in total
Insiders trading
1
Net value
−$950.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Evolus, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Evolus, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Moatazedi DavidSee Remarks499,592Sep 4, 20265
Avelar RuiSee Remarks427,423Mar 20, 20264
Gill David NDirector86,887Feb 19, 20261
White Albert G IIIDirector95,937Feb 19, 20261
Parschauer Karah HerdmanDirector77,742Feb 19, 20261
Malik VikramDirector321,109Feb 19, 20261
Stewart BradyDirector134,188Feb 19, 20261
Mitchell TatjanaChief Financial Officer226,092Feb 19, 20262
Yamagishi-Dressler TomokoChief Marketing Officer89,949Aug 26, 20250
Beaver SandraChief Financial Officer167,089May 14, 20250
Blank SimoneDirector77,111Mar 11, 20250
Hayman RobertDirector54,856Feb 9, 20240
Medytox Inc.Other: Former 10% Owner3,381,326Oct 18, 20230
Alphaeon 1 LLC10% Owner4,214,871Feb 22, 20230
Farrell Peter CDirector43,174Jan 31, 20230
Silvernail Lauren PSee Remarks141,571May 18, 20220
Muilenburg CrystalChief Marketing Officer134,248Mar 10, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 12, 2021 (view filing)Aug 102 daysAvelar RuiSee RemarksSSale−14.3K$11.18−$159.8K−6.4%209.8K after
Aug 12, 2021 (view filing)Aug 102 daysMoatazedi DavidSee RemarksSSale−41.8K$11.18−$466.9K−8.5%447.5K afterAmended
Aug 12, 2021 (view filing)Aug 102 daysSilvernail Lauren PSee RemarksSSale−14.3K$11.18−$159.8K−7.9%166.4K afterAmended
Aug 12, 2021 (view filing)Aug 102 daysMuilenburg CrystalChief Marketing OfficerSSale−5.36K$11.18−$59.9K−5.6%90.7K afterAmended
Aug 13, 2021 (view filing)Aug 11-122 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+65.3K$10.87+$709.4K+1.0%6.83M after2 lots
Aug 17, 2021 (view filing)Aug 13-164 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+114.7K$11.18+$1.28M+1.7%6.94M after2 lots
Aug 17, 2021 (view filing)Aug 13-164 daysMoatazedi DavidSee RemarksSSale−70.4K$11.13−$783.9K−15.7%377.1K after2 lots
Aug 19, 2021 (view filing)Aug 17-182 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+115.0K$10.63+$1.22M+1.7%7.06M after2 lots
Aug 19, 2021 (view filing)Aug 17-182 daysMalik VikramDirectorSSale−67.1K$10.20−$684.4K−5.2%1.23M after2 lots
Aug 20, 2021 (view filing)Aug 19-201 dayMalik VikramDirectorSSale−61.8K$10.59−$654.8K−5.0%1.17M after2 lots
Aug 23, 2021 (view filing)Aug 19-204 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+103.0K$10.53+$1.08M+1.5%7.16M after2 lots
Aug 25, 2021 (view filing)Aug 23-242 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+142.0K$11.10+$1.58M+2.0%7.30M after2 lots
Aug 25, 2021 (view filing)Aug 232 daysMalik VikramDirectorSSale−26.1K$11.00−$286.8K−2.2%1.14M after
Aug 27, 2021 (view filing)Aug 25-262 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+110.0K$11.06+$1.22M+1.5%7.41M after2 lots
Aug 31, 2021 (view filing)Aug 274 daysMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+51.0K$10.93+$557.4K+0.7%7.46M after
Sep 7, 2021 (view filing)Sep 25 daysAlphaeon 1 LLC10% OwnerSSale−2.60M$9.50−$24.7M−30.0%6.06M after
Mar 10, 2022 (view filing)Mar 82 daysSilvernail Lauren PSee RemarksSSale−10.2K$9.73−$99.2K−4.6%209.8K after
Mar 10, 2022 (view filing)Mar 82 daysAvelar RuiSee RemarksSSale−10.2K$9.73−$99.2K−3.9%253.2K after
Mar 10, 2022 (view filing)Mar 82 daysMoatazedi DavidSee RemarksSSale−38.0K$9.73−$369.5K−6.4%553.4K after
Mar 10, 2022 (view filing)Mar 82 daysMuilenburg CrystalChief Marketing OfficerSSale−6.50K$9.73−$63.2K−4.6%134.2K after
Mar 30, 2022 (view filing)Mar 282 daysMoatazedi DavidSee RemarksSSale−6.10K$11.62−$70.9K−1.1%547.3K after
May 17, 2022 (view filing)May 13-164 daysGill David NDirectorSSale−10.3K$13.35−$137.7K−25.9%29.6K after2 lots
May 18, 2022 (view filing)May 17-181 daySilvernail Lauren PSee RemarksSSale−68.2K$12.78−$871.4K−32.5%141.6K after2 lots
May 18, 2022 (view filing)May 162 daysMoatazedi DavidSee RemarksSSale−55.3K$13.64−$754.6K−10.1%492.0K after
Aug 3, 2022 (view filing)Aug 12 daysMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−26.0K$13.28−$345.3K−0.3%7.44M after
Sep 6, 2022 (view filing)Sep 6Same dayFarrell Peter CDirectorPPurchase+10.0K$9.10+$91.0KNew position10.0K after
Sep 8, 2022 (view filing)Sep 62 daysBlank SimoneDirectorPPurchase+20.0K$9.24+$184.8K+57.3%54.9K after
Sep 12, 2022 (view filing)Sep 8-94 daysMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−36.0K$10.47−$376.9K−0.5%7.40M after2 lots
Sep 13, 2022 (view filing)Sep 76 daysHayman RobertDirectorPPurchase+5.00K$10.05+$50.3K+14.3%39.9K afterAmended
Sep 13, 2022 (view filing)Sep 9-124 daysHayman RobertDirectorPPurchase+10.0K$10.40+$104.0KNew position10.0K after2 lots
Sep 16, 2022 (view filing)Sep 14-152 daysMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−97.0K$10.29−$997.9K−1.3%7.30M after2 lots
Oct 6, 2022 (view filing)Oct 51 dayMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−6.85K$8.95−$61.3K−0.1%7.30M after
Oct 7, 2022 (view filing)Oct 61 dayMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−38.3K$8.99−$344.4K−0.5%7.26M after
Feb 6, 2023 (view filing)Aug 12-13, 2021543 daysLateMedytox Inc.10% OwnerPPurchaseCommon Stock, $0.00001 par value per share+37.0K$11.04+$408.8K+0.5%7.30M after2 lots
Feb 6, 2023 (view filing)Jan 2017 daysLateMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−37.0K$11.04−$409.0K−0.5%7.26M after
Feb 8, 2023 (view filing)Feb 71 dayMedytox Inc.10% OwnerSSaleCommon Stock, $0.00001 par value per share−2.19M$8.50−$18.6M−30.1%5.07M after
Feb 22, 2023 (view filing)Feb 175 daysAlphaeon 1 LLC10% OwnerSSaleClass A Common Stock−1.85M$8.40−$15.5M−30.5%4.21M after
Mar 16, 2023 (view filing)Mar 142 daysAvelar RuiSee RemarksSSale−14.9K$8.47−$126.3K−4.2%335.9K after
Mar 16, 2023 (view filing)Mar 142 daysMoatazedi DavidSee RemarksSSale−64.2K$8.47−$543.9K−9.4%615.7K after
Mar 29, 2023 (view filing)Mar 272 daysMoatazedi DavidSee RemarksSSale−6.11K$8.47−$51.8K−1.0%609.6K after10b5-1
Aug 15, 2023 (view filing)Aug 15Same dayMalik VikramDirectorPPurchase+175.0K$7.41+$1.30M+174.0%275.6K after
Aug 16, 2023 (view filing)Aug 16Same dayMoatazedi DavidSee RemarksSSale−14.8K$10.27−$151.8K−2.1%686.6K after10b5-1
Aug 16, 2023 (view filing)Aug 16Same dayBeaver SandraChief Financial OfficerSSale−2.21K$10.27−$22.7K−1.9%116.5K after10b5-1
Aug 16, 2023 (view filing)Aug 16Same dayAvelar RuiSee RemarksSSale−2.21K$10.27−$22.7K−0.6%353.4K after10b5-1
Sep 8, 2023 (view filing)Sep 62 daysBeaver SandraChief Financial OfficerSSale−3.18K$9.70−$30.8K−2.7%113.4K after10b5-1
Oct 18, 2023 (view filing)Oct 162 daysMedytox Inc.Other: Former 10% OwnerSSaleCommon Stock, $0.00001 par value per share−1.69M$7.50−$12.7M−33.3%3.38M after
Dec 8, 2023 (view filing)Dec 6-82 daysMoatazedi DavidSee RemarksSSale−82.6K$9.95−$822.7K−12.0%603.9K after2 lots
Feb 2, 2024 (view filing)Jan 303 daysLateParschauer Karah HerdmanDirectorSSale−11.9K$13.14−$156.8K−27.6%31.2K after10b5-1
Feb 23, 2024 (view filing)Feb 221 dayBeaver SandraChief Financial OfficerSSale−1.82K$13.08−$23.8K−1.1%159.9K after10b5-1
Feb 23, 2024 (view filing)Feb 221 dayAvelar RuiSee RemarksSSale−1.82K$13.08−$23.8K−0.5%399.9K after10b5-1